Dr Teng on the Phase 2 CARES-005 Study of TACE Plus Camrelizumab and Rivoceranib in Unresectable HCC 

Gao-Jun Teng, MD, of Zhongda Hospital, Medical School, Southeast University, discusses findings from the phase 2 CARES-005 trial (NCT04559607) of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable hepatocellular carcinoma.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Hepatocellular Carcinoma

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Gastrointestinal Cancers Symposium (ASCO GI)

Gao-Jun Teng, MD, discusses findings from the phase 2 CARES-005 trial of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable HCC.